These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
621 related articles for article (PubMed ID: 26541815)
1. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. Stroup TS; Gerhard T; Crystal S; Huang C; Olfson M Am J Psychiatry; 2016 Feb; 173(2):166-73. PubMed ID: 26541815 [TBL] [Abstract][Full Text] [Related]
2. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. Nielsen J; Nielsen RE; Correll CU J Clin Psychopharmacol; 2012 Oct; 32(5):678-83. PubMed ID: 22926603 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of clozapine use in delaying hospitalization in routine clinical practice: a 2 year observational study. Nyakyoma K; Morriss R Psychopharmacol Bull; 2010; 43(2):67-81. PubMed ID: 21052043 [TBL] [Abstract][Full Text] [Related]
4. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. Velligan DI; Carroll C; Lage MJ; Fairman K Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616 [TBL] [Abstract][Full Text] [Related]
6. Hyperlipidemia following treatment with antipsychotic medications. Olfson M; Marcus SC; Corey-Lisle P; Tuomari AV; Hines P; L'Italien GJ Am J Psychiatry; 2006 Oct; 163(10):1821-5. PubMed ID: 17012695 [TBL] [Abstract][Full Text] [Related]
7. Risk of cerebrovascular adverse events in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. Mehta S; Johnson ML; Chen H; Aparasu RR J Clin Psychiatry; 2010 Jun; 71(6):689-98. PubMed ID: 20573328 [TBL] [Abstract][Full Text] [Related]
8. Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital. Stone-Brown K; Naji M; Francioni A; Myers K; Samarendra H; Mushtaq-Chaudhry H; Heslop S; Sengupta S; Ross CC; Larkin F; Das M CNS Spectr; 2016 Feb; 21(1):60-9. PubMed ID: 26726766 [TBL] [Abstract][Full Text] [Related]
9. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741 [TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia. Stroup TS; Gerhard T; Crystal S; Huang C; Tan Z; Wall MM; Mathai C; Olfson M JAMA Psychiatry; 2019 May; 76(5):508-515. PubMed ID: 30785609 [TBL] [Abstract][Full Text] [Related]
11. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Wheeler AJ Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732 [TBL] [Abstract][Full Text] [Related]
12. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216 [TBL] [Abstract][Full Text] [Related]
13. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia. Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926 [TBL] [Abstract][Full Text] [Related]
14. Community Evidence of Clozapine's Effectiveness. Marder SR Am J Psychiatry; 2016 Feb; 173(2):103-4. PubMed ID: 26844790 [No Abstract] [Full Text] [Related]
15. Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia. Wimberley T; MacCabe JH; Laursen TM; Sørensen HJ; Astrup A; Horsdal HT; Gasse C; Støvring H Am J Psychiatry; 2017 Oct; 174(10):990-998. PubMed ID: 28750580 [TBL] [Abstract][Full Text] [Related]
16. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334 [TBL] [Abstract][Full Text] [Related]
17. Antipsychotic prescription filling in patients with schizophrenia or schizoaffective disorder. Reutfors J; Brandt L; Stephansson O; Kieler H; Andersen M; Bodén R J Clin Psychopharmacol; 2013 Dec; 33(6):759-65. PubMed ID: 24126686 [TBL] [Abstract][Full Text] [Related]
18. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014. Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308 [TBL] [Abstract][Full Text] [Related]
19. Geographic and clinical variation in clozapine use in the United States. Stroup TS; Gerhard T; Crystal S; Huang C; Olfson M Psychiatr Serv; 2014 Feb; 65(2):186-92. PubMed ID: 24233347 [TBL] [Abstract][Full Text] [Related]
20. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Mortimer AM; Singh P; Shepherd CJ; Puthiryackal J Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):49-55. PubMed ID: 20643629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]